{"generic":"Norethindrone","drugs":["Camila","Errin","Jolivette","Lyza","Nor-QD","Nora-BE","Norethindrone","Ortho Micronor"],"mono":[{"id":"8si9s0","title":"Generic Names","mono":"Norethindrone"},{"id":"8si9s1","title":"Dosing and Indications","sub":{"0":{"id":"8si9s1b4","title":"Adult Dosing","mono":"<ul><li>Switch from a 21-day regimen of oral contraceptive by starting first dose after completion of active tablets. Switch from a 28-day regimen of oral contraceptive by starting first dose after completion of active tablets and skipping inactive tablets. Switch from another progestin-only pill at any time.<\/li><li>If breastfeeding, may switch to another method of birth control at any time; do not switch to the combination oral contraceptive until breastfeeding is stopped or until at least 6 months after delivery.<\/li><li><b>Contraception:<\/b> 1 tablet ORALLY daily at the same time of day; administration is continuous between pill packs.<\/li><li><b>Contraception:<\/b> Begin therapy on the first day of menstrual cycle; if dosing starts on a day other than the first day of menstrual cycle, a nonhormonal backup method of contraception is recommended for the first 48 hours of therapy.<\/li><li><b>Contraception:<\/b> Therapy may be initiated 6 weeks postpartum in fully lactating (no formula) women or 3 weeks postpartum in partially lactating (some formula) women.<\/li><li><b>Contraception:<\/b> Therapy may be initiated on the next day following an abortion or miscarriage.<\/li><\/ul>"},"1":{"id":"8si9s1b5","title":"Pediatric Dosing","mono":"<ul><li>Use before menarche is not indicated.<\/li><li>Switch from a 21-day regimen of oral contraceptive by starting first dose after completion of active tablets. Switch from a 28-day regimen of oral contraceptive by starting first dose after completion of active tablets and skipping inactive tablets. Switch from another progestin-only pill at any time.<\/li><li>If breastfeeding, may switch to another method of birth control at any time; do not switch to the combination oral contraceptive until breastfeeding is stopped or until at least 6 months after delivery.<\/li><li><b>Contraception:<\/b> After menarche: 1 tablet ORALLY daily at the same time of day; administration is continuous between pill packs.<\/li><li><b>Contraception:<\/b> Begin therapy on the first day of menstrual cycle; if dosing starts on a day other than the first day of menstrual cycle, a nonhormonal backup method of contraception is recommended for the first 48 hours of therapy.<\/li><li><b>Contraception:<\/b> Therapy may be initiated 6 weeks postpartum in fully lactating (no formula) women or 3 weeks postpartum in partially lactating (some formula) women.<\/li><li><b>Contraception:<\/b> Therapy may be initiated on the next day following an abortion or miscarriage.<\/li><\/ul>"},"3":{"id":"8si9s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Contraception<br\/>"}}},{"id":"8si9s2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Cigarette smoking greatly increases the possibility of suffering heart attacks and strokes. Women who use oral contraceptives are strongly advised not to smoke.<br\/>"},{"id":"8si9s3","title":"Contraindications\/Warnings","sub":[{"id":"8si9s3b9","title":"Contraindications","mono":"<ul><li>Abnormal and undiagnosed genital bleeding<\/li><li>Acute liver disease<\/li><li>Benign or malignant liver tumors<\/li><li>Carcinoma of the breast<\/li><li>Hypersensitivity to any component of the product<\/li><li>Pregnancy<\/li><\/ul>"},{"id":"8si9s3b10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Increased risk of serious cardiovascular disease with cigarette use; women who use oral contraceptives are strongly advised not to smoke<\/li><li>Endocrine and Metabolic:<\/li><li>-- Changes in carbohydrate or lipid metabolism may occur, particularly in diabetic and prediabetic patients; monitoring recommended<\/li><li>Hepatic:<\/li><li>-- Benign hepatic adenomas and an increased risk of hepatocellular carcinoma have been reported with combined oral contraceptive use<\/li><li>Neurologic:<\/li><li>-- New onset or worsening of migraine or severe headaches with focal neurological symptoms have been reported; discontinue use and evaluate cause<\/li><li>Reproductive:<\/li><li>-- Increased risk of breast cancer has been reported with combined oral contraceptive use<\/li><li>-- Ectopic pregnancy may occur<\/li><li>-- Delayed follicular atresia and ovarian cysts have been reported; surgical intervention may be required<\/li><li>-- Irregular menstrual patterns may occur; rule out pregnancy if prolonged amenorrhea occurs<\/li><li>-- Does not protect against sexually transmitted diseases<\/li><\/ul>"},{"id":"8si9s3b11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"8si9s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"8si9s4","title":"Drug Interactions","sub":[{"id":"8si9s4b13","title":"Contraindicated","mono":"<ul>Tranexamic Acid (probable)<\/ul>"},{"id":"8si9s4b14","title":"Major","mono":"<ul><li>Aripiprazole (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Isotretinoin (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Tizanidine (probable)<\/li><li>Ulipristal (established)<\/li><\/ul>"},{"id":"8si9s4b15","title":"Moderate","mono":"<ul><li>Alprazolam (probable)<\/li><li>Amprenavir (probable)<\/li><li>Aprepitant (probable)<\/li><li>Atazanavir (probable)<\/li><li>Bacampicillin (probable)<\/li><li>Betamethasone (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bosentan (probable)<\/li><li>Colesevelam (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Delavirdine (probable)<\/li><li>Etravirine (probable)<\/li><li>Fosamprenavir (established)<\/li><li>Fosaprepitant (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Griseofulvin (established)<\/li><li>Lamotrigine (established)<\/li><li>Licorice (probable)<\/li><li>Modafinil (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><li>Mycophenolic Acid (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Oxcarbazepine (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Prednisolone (established)<\/li><li>Primidone (probable)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>Ritonavir (probable)<\/li><li>Rosuvastatin (probable)<\/li><li>Rufinamide (probable)<\/li><li>Selegiline (probable)<\/li><li>St John's Wort (established)<\/li><li>Telaprevir (established)<\/li><li>Topiramate (probable)<\/li><li>Troglitazone (probable)<\/li><li>Troleandomycin (established)<\/li><li>Valdecoxib (probable)<\/li><li>Voriconazole (established)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},{"id":"8si9s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Nausea<\/li><li><b>Neurologic:<\/b>Headache<\/li><li><b>Reproductive:<\/b>Abnormal menstrual cycle, Breast tenderness, Irregular periods<\/li><\/ul><b>Serious<\/b><br\/><b>Reproductive:<\/b>Ectopic pregnancy<br\/>"},{"id":"8si9s6","title":"Drug Name Info","sub":{"0":{"id":"8si9s6b17","title":"US Trade Names","mono":"<ul><li>Camila<\/li><li>Errin<\/li><li>Jolivette<\/li><li>Lyza<\/li><li>Nor-QD<\/li><li>Nora-BE<\/li><li>Ortho Micronor<\/li><\/ul>"},"2":{"id":"8si9s6b19","title":"Class","mono":"<ul><li>Contraceptive, Progestin<\/li><li>Endocrine-Metabolic Agent<\/li><li>Progestin<\/li><\/ul>"},"3":{"id":"8si9s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"8si9s6b21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"8si9s7","title":"Mechanism Of Action","mono":"Norethindrone is a progestin contraceptive that prevents ovulation, inhibits sperm penetration by thickening the cervical mucus, reduces the midcycle luteinizing hormone and follicle-stimulating hormone peaks, delays the movement of ovum through the fallopian tube, and alters the endometrium lining.<br\/>"},{"id":"8si9s8","title":"Pharmacokinetics","sub":[{"id":"8si9s8b23","title":"Absorption","mono":"<ul><li>Rate of absorption, Oral: rapid<\/li><li>Tmax, Oral: 1 to 2 hours<\/li><li>Bioavailability, Oral: 65%<\/li><\/ul>"},{"id":"8si9s8b24","title":"Distribution","mono":"<ul><li>Protein binding: sex hormone-binding globulin, 36%; albumin, 61%<\/li><li>Vd: 4 L\/kg<\/li><\/ul>"},{"id":"8si9s8b25","title":"Metabolism","mono":"<ul><li>Hepatic: extensive via reduction and conjugation<\/li><li>Sulfate conjugates (unknown): major circulation metabolites<\/li><li>Glucuronide conjugates (unknown): major urinary metabolites<\/li><\/ul>"},{"id":"8si9s8b26","title":"Excretion","mono":"<ul><li>Renal: greater than 50% (primarily metabolites); less than 5% unchanged<\/li><li>Feces: 20% to 43% (primarily metabolites); less than 5% unchanged<\/li><li>Total body clearance: 600 L\/day<\/li><\/ul>"},{"id":"8si9s8b27","title":"Elimination Half Life","mono":"8 hours <br\/>"}]},{"id":"8si9s9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>Take exactly as directed and at the same time of day.<\/li><li>Administration is continuous between pill packs.<\/li><li>Missed doses: If dose is delayed by more than 3 hours, take the missed dose as soon as remembered; nonhormonal backup contraception is recommended for the next 48 hours of therapy.<\/li><li>Missed doses (including vomiting soon after dose): With 1 or more missed doses, take a missed dose as soon as remembered; nonhormonal backup contraception is recommended for the next 48 hours of therapy.<\/li><\/ul>"},{"id":"8si9s10","title":"Monitoring","mono":"<ul><li>prevention of unintended pregnancy is indicative of efficacy<\/li><li>glucose tolerance and insulin requirements in prediabetic and diabetic women<\/li><li>annual history and physical examination for all sexually active women using oral contraceptives<\/li><\/ul>"},{"id":"8si9s11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 0.35 MG<br\/><\/li><li><b>Camila<\/b><br\/>Oral Tablet: 0.35 MG<br\/><\/li><li><b>Deblitane<\/b><br\/>Oral Tablet: 0.35 MG<br\/><\/li><li><b>Errin<\/b><br\/>Oral Tablet: 0.35 MG<br\/><\/li><li><b>Heather<\/b><br\/>Oral Tablet: 0.35 MG<br\/><\/li><li><b>Jencycla<\/b><br\/>Oral Tablet: 0.35 MG<br\/><\/li><li><b>Lyza<\/b><br\/>Oral Tablet: 0.35 MG<br\/><\/li><li><b>Nora-BE<\/b><br\/>Oral Tablet: 0.35 MG<br\/><\/li><li><b>Norlyroc<\/b><br\/>Oral Tablet: 0.35 MG<br\/><\/li><li><b>Nor-QD<\/b><br\/>Oral Tablet: 0.35 MG<br\/><\/li><li><b>Ortho Micronor<\/b><br\/>Oral Tablet: 0.35 MG<br\/><\/li><li><b>Sharobel<\/b><br\/>Oral Tablet: 0.35 MG<br\/><\/li><\/ul>"},{"id":"8si9s12","title":"Toxicology","sub":[{"id":"8si9s12b31","title":"Clinical Effects","mono":"<b>PROGESTINS<\/b><br\/>OVERDOSE:  Rarely do acute ingestions result in obvious clinical manifestations.  CHRONIC: Most  adverse effects are related to chronic or high-dose therapy.  Headache, dizziness, irregular menses, mastalgia, bloating, depression, decreased libido, cholestatic jaundice, hepatitis, oligomenorrhea, amenorrhea and thromboembolism may occur with chronic therapy.<br\/>"},{"id":"8si9s12b32","title":"Treatment","mono":"<b>PROGESTINS <\/b><br\/><ul><li>Support: Single acute overdoses will seldom result in toxicity.  Supportive treatment is adequate in most situations.<\/li><li>Decontamination: Gastric decontamination is probably only necessary after very large ingestions or with toxic coingestants; administer activated charcoal in these cases.<\/li><li>Monitoring of patient: CHRONIC TOXICITY: Discontinue medication and monitor for signs of toxicity and treat symptomatically.  Obtain a baseline CBC and hepatic and renal function tests in symptomatic patients.<\/li><\/ul>"},{"id":"8si9s12b33","title":"Range of Toxicity","mono":"<b>PROGESTINS<\/b><br\/>Toxicity is unlikely following an acute overdose.  There are insufficient data reported in the literature to assess the range of toxicity in terms of mg\/kg ingested. <br\/>"}]},{"id":"8si9s13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to practice safe sex. Drug does not protect against sexually transmitted diseases.<\/li><li>Drug may cause nausea, dizziness, headache, breast tenderness, or irregular periods.<\/li><li>Tell patient to report persistent or recurrent abnormal vaginal bleeding, amenorrhea, or severe abdominal pain.<\/li><li>Advise patient to take drug every day, at the same time of day, with no more than 24 hours between doses, including during bleeding episodes.<\/li><li>Patient should not smoke during therapy, as this increases the risk of heart attack or stroke.<\/li><li>Review with patient the procedure for handling a missed dose.<\/li><\/ul>"}]}